01099cam0 2200301 450 E60020007319120201209120142.020110329d1982 |||||ita|0103 bagrcITIl buon re secondo OmeroFilodemoedizione, traduzione e commento a cura di Tiziano DorandiNapoliBibliopolis1982234 p.24 cm<La >scuola di Epicuro3001LAEC000264442001 La *scuola di Epicuro3PhilodemusA600200064655070155469DORANDI, TizianoAF00021801070ITUNISOB20201209RICAUNISOBUNISOB10060182UNISOB87060258E600200073191M 102 Monografia moderna SBNM100005376Si60182massimoUNISOBUNISOB20110329114655.020201209120129.0Alfano870000573SI60258AcquistoNpetrellapUNISOBUNISOB20151111141347.020151111141420.0petrellapBuon re secondo Omero475819UNISOB03606nam 22005775 450 991103457280332120251004130452.03-031-97397-610.1007/978-3-031-97397-0(CKB)41571885300041(MiAaPQ)EBC32334632(Au-PeEL)EBL32334632(DE-He213)978-3-031-97397-0(OCoLC)1545124380(EXLCZ)994157188530004120251004d2026 u| 0engur|||||||||||txtrdacontentcrdamediacrrdacarrierPraziquantel Discovery and Development of an Anthelmintic Drug /edited by Thomas Spangenberg1st ed. 2026.Cham :Springer Nature Switzerland :Imprint: Springer,2026.1 online resource (318 pages)Biomedical and Life Sciences Series3-031-97396-8 Chapter 1: A Brief History of the Pharmaceutical Industry -- Chapter 2: The Parasite`s Life Cycle and the Patient -- Chapter 3: The Medical Need for Patients with Schistosomiasis -- Chapter 4: From Small Molecule to Drug Product, the Chemical Journey of Praziquantel -- Chapter 5: The Molecular Drug Target of Praziquantel -- Chapter 6: In Vitro and In Vivo Activity of Praziquantel Against Schistosome Worms -- Chapter 7: In Life Behaviour of Praziquantel & Relationship Between Drug Exposure and Effect -- Chapter 8: Nonclinical safety of Praziquantel -- Chapter 9: Controlled Human Schistosoma mansoni Infection Model & Biomarkers -- Chapter 10: Clinical efficacy of Praziquantel on Schistosoma Infections -- Chapter 11: Regulators’ Viewpoint -- Chapter 12: Proprietary Aspects of Praziquantel.This open-access book provides a comprehensive reference on the discovery and development of praziquantel. It presents the full research and development (R&D) journey of this essential anthelmintic drug, combining foundational science with practical insights. The book covers a wide range of topics, including a brief history of pharmaceutical industry, unmet medical needs, parasitic flatworm biology, and strategies for schistosomiasis control and elimination. Both human and animal health applications are addressed. Additional chapters explore chemical and manufacturing aspects, drug targets, biomarkers, toxicology, clinical efficacy, regulatory pathways, and Intellectual Property considerations. Rich illustrations, expert commentary, and clear summaries enhance the educational value of the text. Designed for students, academics, and industry professionals alike, this volume serves as a valuable addition to any scientific library. It also supports the United Nations Sustainable Development Goal 3 (Good Health and Well-being) by contributing to the global fight against schistosomiasis and other Neglected Tropical Diseases.Biomedical and Life Sciences SeriesParasitologyPharmacologyPharmacovigilanceParasitologyPharmacologyDrug Safety and PharmacovigilanceParasitology.Pharmacology.Pharmacovigilance.Parasitology.Pharmacology.Drug Safety and Pharmacovigilance.571.999Spangenberg Thomas1853271MiAaPQMiAaPQMiAaPQBOOK9911034572803321Praziquantel4449373UNINA